

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/835,996	04/16/2001	Dennis G. Ballinger	28110/35915A	6033
7590 03/18/2004			EXAMINER	
LI-HSIEN RIN-LAURES			TUNG, JOYCE	
HYSEQ, INC. 670 ALMANOR AVENUE			ART UNIT	PAPER NUMBER
SUNNYVALE, CA 94085			1637	

DATE MAILED: 03/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

n, od	Application No.	Applicant(s)			
	09/835,996	BALLINGER ET AL.			
Office Action Summary	Examiner	Art Unit			
•	Joyce Tung	1637			
The MAILING DATE of this communica					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNIC. - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commun. - If the period for reply specified above is less than thirty (30) (and if the period for reply is specified above, the maximum statuting the period for reply with the set or extended period for reply will any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	ATION. 37 CFR 1.136(a). In no event, however, may a dication. days, a reply within the statutory minimum of the tory period will apply and will expire SIX (6) MC II, by statute, cause the application to become a	a reply be timely filed irty (30) days will be considered timely. INTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed	on 30 December 2003.				
•					
3) Since this application is in condition fo					
closed in accordance with the practice	under <i>Ex parte Quayle</i> , 1935 C.	D. 11, 453 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>10-12</u> is/are pending in the ap	oplication.				
	4a) Of the above claim(s) is/are withdrawn from consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1012</u> is/are rejected.	· / 				
7)☐ Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction	on and/or election requirement.				
Application Papers					
9)☐ The specification is objected to by the I	Examiner.				
10) The drawing(s) filed on is/are: a	☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.				
Applicant may not request that any objection	on to the drawing(s) be held in abeya	ance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including th	ne correction is required if the drawin	g(s) is objected to. See 37 CFR 1.121(d).			
11)☐ The oath or declaration is objected to b	by the Examiner. Note the attache	ed Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
	ocuments have been received. Ocuments have been received in the priority documents have been all Bureau (PCT Rule 17.2(a)).	Application No n received in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview	Summary (PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTC	D-948) Paper No	o(s)/Mail Date Informal Patent Application (PTO-152)			
 Information Disclosure Statement(s) (PTO-1449 or PT Paper No(s)/Mail Date <u>03212002</u>. 	6) Other: _				

Application/Control Number: 09/835,996

Art Unit: 1637

DETAILED ACTION

Following the entry of the amendment filed 12/30/2003, the claims 10-12 are pending.

Election/Restrictions

1. Applicant's election with traverse of Group III, claims 10-12 in Paper No. 12302003 is acknowledged. The traversal is on the ground(s) that Groups I-III should be examined simultaneously. However, Groups I-II, claims 1-9 and Groups IV-IX, claims 13-20 were canceled. The arguments are moot.

The requirement is still deemed proper and is therefore made FINAL.

Specification

2. The title of the invention is not descriptive because the instant claims are drawn to a polypeptide amino acid sequence. A new title is required that is clearly indicative of the invention to which the claims are directed.

Claim Rejections - 35 USC § 101

3. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 10-12 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.

As disclosed in the specification, there are multiple utilities listed for the proteins of the instant invention comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 or 45, for example, apoprotein, lipase or lipoprotein receptor activity (See pg. 33, lines 9-14 and pg. 65, lines 14-31 of the specification).

Art Unit: 1637

However, the specification does not disclose a specific utility for the polypeptide comprising SEQ ID NO: 27.

4. Claims 10-12 is also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 11-12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification disclose four variant nucleotide sequences set forth in SEQ ID NO: 22, 24, 26 and 44 and their respective deduced amino acid sequences set forth in SEQ ID NO: 23, 25, 27, and 45 in which the polypeptide amino acid sequence, SEQ ID NO: 27 is encoded by the nucleic acid sequence, SEQ ID NO: 26 (See pg. 48 of the Sequence Listing). There is no further descriptions of the variants provided regarding one or more amino acid substitutions, deletions, insertions and/or additions of a polypeptide amino acid sequence to have the polypeptide having

Application/Control Number: 09/835,996

Art Unit: 1637

1627

greater than about 90% sequence identity with the polypeptide amino acid, SEQ ID NO: 27.

Page 4

Thus, one of skill in the art would conclude that applicant was not in possession of the claimed

genus because a description of only one member of this genus is not representative of the

variants of the genus and is insufficient to support the claim.

Summary

7. No claims are allowed.

8. Any inquiries concerning this communication or earlier communications from the

examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The

examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-

6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be

directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

9. Papers related to this application may be submitted to Group 1600 by facsimile

transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal

Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the

notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung $\int \int$ March 11, 2004

ETHAN WHISENANT PRIMARY EXAMINED